Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain

In the first quarter of 2025, an estimated 4.9 million adults in Great Britain-nearly one in ten-either had recently used a GLP-1 or GLP-1/GIP medication to support weight loss or were interested in doing so in the near future. A substantial minority reported using a type of GLP-1 medication that was not licensed for weight management, suggesting off-label use. Interest was particularly high among less advantaged socioeconomic groups, while use was similar across groups, highlighting the importance of addressing equity in access. These findings underscore the need to monitor who is accessing these medications and to ensure their safe, appropriate, and equitable provision.